Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers co-driven by mutant EGFR containing T790M and MET

Tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR) are effective in most NSCLC patients whose tumors harbor activating EGFR kinase domain mutations. Unfortunately, acquired resistance eventually emerges in these chronically treated cancers. Two of the most comm...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Xu, Lu, Kikuchi, Eiki, Xu, Chunxiao, Ebi, Hiromichi, Ercan, Dalia, Cheng, Katherine A., Padera, Robert, Engelman, Jeffrey A., Jänne, Pasi A., Shapiro, Geoffrey I., Shimamura, Takeshi, Wong, Kwok-Kin
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3389159/
https://ncbi.nlm.nih.gov/pubmed/22552292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-3720
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares